Agreement licenses the rights for a promising hemophilia B gene therapy.
News & Analysis: uniQure
Here are the biotechs most likely to receive juicy buyout offers in 2020.
The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.
Investor optimism is surging following recent M&A in gene therapy.
Steady progress with experimental gene therapies gave investors reasons to cheer.
Good news has a way of attracting suitors.
Roche's big step into the gene-editing space will spark interest for these two stocks.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.
Great clinical results for its experimental hemophilia B gene therapy lit a fire beneath this biotech stock.
Is continued success in the cards for these biotech stocks?